# CareDx, Inc.: overview

CDNA · Nasdaq · CIK 1217234 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cdna.md) · [Financials](/companies/cdna/financials.md) · [Filings](/companies/cdna/filings.md) · [Insiders](/companies/cdna/insiders.md)

Latest reported revenue: [$139.4m](/filings/0001217234-26-000061.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001217234-26-000061).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [86.6 d](/filings/0001217234-26-000018.md) | [84.7](/filings/0001217234-26-000033.md) | [86.7](/filings/0001217234-26-000046.md) | [100](/filings/0001217234-26-000061.md) | [108 d](/filings/0001217234-26-000018.md) | [118](/filings/0001217234-26-000033.md) | [132](/filings/0001217234-26-000046.md) | [139](/filings/0001217234-26-000061.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [97.5% d](/filings/0001217234-26-000018.md) | [(15.8%)](/filings/0001217234-26-000033.md) | [(12.8%)](/filings/0001217234-26-000046.md) | [(0.2%)](/filings/0001217234-26-000061.md) | [(5.6%) d](/filings/0001217234-26-000018.md) | [1.0%](/filings/0001217234-26-000033.md) | [85.8%](/filings/0001217234-26-000046.md) | [5.8%](/filings/0001217234-26-000061.md) |
| Net margin | % | [101.3% d](/filings/0001217234-26-000018.md) | [(12.2%)](/filings/0001217234-26-000061.md) | [(9.9%)](/filings/0001217234-26-000061.md) | [1.7%](/filings/0001217234-26-000061.md) | [(3.8%) d](/filings/0001217234-26-000018.md) | [2.4%](/filings/0001217234-26-000061.md) | [83.8%](/filings/0001217234-26-000061.md) | [13.8%](/filings/0001217234-26-000061.md) |
| Diluted EPS | $ per share | not reported | [(0.19)](/filings/0001217234-26-000033.md) | [(0.16)](/filings/0001217234-26-000046.md) | [0.03](/filings/0001217234-26-000061.md) | not reported | [0.05](/filings/0001217234-26-000033.md) | [2.07](/filings/0001217234-26-000046.md) | [0.35](/filings/0001217234-26-000061.md) |
| Free cash flow | $m | not reported | [(28.2)](/filings/0001217234-26-000033.md) | [8.9 d](/filings/0001217234-26-000046.md) | [36.1 d](/filings/0001217234-26-000061.md) | not reported | [0.5](/filings/0001217234-26-000033.md) | [28.7 d](/filings/0001217234-26-000046.md) | [11.1 d](/filings/0001217234-26-000061.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [296](/filings/0001217234-24-000033.md) | [322](/filings/0001217234-25-000012.md) | [280](/filings/0001217234-26-000018.md) | [334](/filings/0001217234-26-000018.md) | [380](/filings/0001217234-26-000018.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(10.0%)](/filings/0001217234-24-000033.md) | [(24.0%)](/filings/0001217234-25-000012.md) | [(72.5%)](/filings/0001217234-26-000018.md) | [12.2%](/filings/0001217234-26-000018.md) | [(8.1%)](/filings/0001217234-26-000018.md) |
| Net margin | % | [(10.3%)](/filings/0001217234-24-000033.md) | [(23.8%)](/filings/0001217234-25-000012.md) | [(67.9%)](/filings/0001217234-26-000018.md) | [15.7%](/filings/0001217234-26-000018.md) | [(5.6%)](/filings/0001217234-26-000018.md) |
| Diluted EPS | $ per share | [(0.59)](/filings/0001217234-24-000033.md) | [(1.44)](/filings/0001217234-25-000012.md) | [(3.54)](/filings/0001217234-26-000018.md) | [0.93](/filings/0001217234-26-000018.md) | [(0.40)](/filings/0001217234-26-000018.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cdna/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $137.2m | 4,814,709 |  | Added +292,613 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $70.4m | 2,468,858 |  | Reduced −291,527 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $62.6m | 2,197,475 |  | Added +37,018 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $56.9m | 1,997,618 |  | Reduced −193,382 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $55.7m | 1,953,531 |  | Reduced −274,025 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $55.2m | 1,937,601 |  | Added +54,067 |
| [BAMCO INC /NY/](/funds/1017918.md) | 2026-06-30 | $55.2m | 1,937,326 |  | Reduced −1,399,083 |
| [GAGNON SECURITIES LLC](/funds/1125725.md) | 2026-06-30 | $50.5m | 1,770,735 |  | Added +8,861 |
| [Chevy Chase Trust Holdings, LLC](/funds/1462020.md) | 2026-06-30 | $41.0m | 1,437,416 |  | Reduced −66,659 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $37.9m | 1,328,037 |  | Added +73,923 |

## Recent filings

[All 1,378 filings](/companies/cdna/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:04 ET | [10-Q](/filings/0001217234-26-000061.md) | Quarterly report, period 2026-09-30 | 0001217234-26-000061 |
| 2026-10-29 | 16:02 ET | [8-K](/filings/0001217234-26-000059.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001217234-26-000059 |
| 2026-09-16 | 16:06 ET | [8-K/A](/filings/0001217234-26-000052.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001217234-26-000052 |
| 2026-07-30 | 16:04 ET | [10-Q](/filings/0001217234-26-000046.md) | Quarterly report, period 2026-06-30 | 0001217234-26-000046 |
| 2026-07-30 | 16:03 ET | [8-K](/filings/0001217234-26-000045.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001217234-26-000045 |
| 2026-07-07 | 17:12 ET | [8-K](/filings/0001217234-26-000038.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001217234-26-000038 |
| 2026-06-15 | 16:15 ET | [8-K](/filings/0001217234-26-000036.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001217234-26-000036 |
| 2026-04-28 | 16:13 ET | [10-Q](/filings/0001217234-26-000033.md) | Quarterly report, period 2026-03-31 | 0001217234-26-000033 |
| 2026-04-28 | 16:05 ET | [8-K](/filings/0001104659-26-050317.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-050317 |
| 2026-04-27 | 16:06 ET | [DEF 14A](/filings/0001217234-26-000028.md) | Proxy statement, period 2026-04-27 | 0001217234-26-000028 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001217234-26-000018.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/4031b8cf-9958-45ad-8890-ab05efac99fc)

## About the filer

- CIK: 1217234
- Tickers: CDNA
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:39 ET. No prices; not investment advice.